{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Detroit&page=53&state=Michigan", "query": { "state": "Michigan", "city": "Detroit", "page": 53 }, "page_size": 10 }, "pagination": { "page": 53, "page_size": 10, "total_count": 7248, "total_pages": 725, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Detroit&page=54&state=Michigan&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Detroit&page=52&state=Michigan&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-07T22:27:56.106Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00088504", "title": "Merimepodib (MMPD) in Triple Combination for the Treatment of Chronic Hepatitis C", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C", "Hepatitis" ], "interventions": [ { "name": "Merimepodib", "type": "DRUG" }, { "name": "PEG-Interferon-alpha 2a (Pegasys®)", "type": "DRUG" }, { "name": "Ribavirin (Copegus®)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 315, "start_date": "2004-07", "completion_date": "2006-10", "has_results": false, "last_update_posted_date": "2007-12-21", "last_synced_at": "2026-11-07T22:27:56.106Z", "location_count": 67, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 55 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Fresno", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00088504" }, { "nct_id": "NCT04416984", "title": "Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "ALLO-501A", "type": "GENETIC" }, { "name": "ALLO-647", "type": "BIOLOGICAL" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "GENETIC", "BIOLOGICAL", "DRUG" ], "sponsor": "Allogene Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 160, "start_date": "2020-05-21", "completion_date": "2029-05", "has_results": false, "last_update_posted_date": "2026-03-04", "last_synced_at": "2026-11-07T22:27:56.106Z", "location_count": 24, "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Duarte, California + 21 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04416984" }, { "nct_id": "NCT07450547", "title": "Phase 2 Study to Assess the Safety and Efficacy of ANG003", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Exocrine Pancreatic Insufficiency (EPI)", "Cystic Fibrosis (CF)" ], "interventions": [ { "name": "ANG003 Dose A", "type": "DRUG" }, { "name": "ANG003 Dose B", "type": "DRUG" }, { "name": "Creon", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Anagram Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 113, "start_date": "2026-04-24", "completion_date": "2027-07", "has_results": false, "last_update_posted_date": "2026-10-30", "last_synced_at": "2026-11-07T22:27:56.106Z", "location_count": 28, "location_summary": "Long Beach, California • Los Angeles, California • Denver, Colorado + 24 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07450547" }, { "nct_id": "NCT02648347", "title": "Study to Evaluate Vadadustat for the Correction of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Anemia", "Non-Dialysis-Dependent Chronic Kidney Disease" ], "interventions": [ { "name": "Vadadustat", "type": "DRUG" }, { "name": "Darbepoetin alfa", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Akebia Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1751, "start_date": "2015-12", "completion_date": "2020-07-31", "has_results": true, "last_update_posted_date": "2022-06-27", "last_synced_at": "2026-11-07T22:27:56.106Z", "location_count": 208, "location_summary": "Huntsville, Alabama • Tuscumbia, Alabama • Glendale, Arizona + 148 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Tuscumbia", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02648347" }, { "nct_id": "NCT00298558", "title": "ACTIVE: Advanced Cognitive Training for Independent and Vital Elderly", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Aging", "Healthy" ], "interventions": [ { "name": "Cognitive Training", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Carelon Research", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "65 Years", "maximum_age": null, "sex": "ALL", "summary": "65 Years and older" }, "enrollment_count": 2832, "start_date": "1998-03", "completion_date": "2010-12", "has_results": true, "last_update_posted_date": "2014-04-16", "last_synced_at": "2026-11-07T22:27:56.106Z", "location_count": 7, "location_summary": "Birmingham, Alabama • Indianapolis, Indiana • Baltimore, Maryland + 4 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Cumberland", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00298558" }, { "nct_id": "NCT04814732", "title": "Expanded Access Program of Surufatinib", "overall_status": "NO_LONGER_AVAILABLE", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "Neuroendocrine Tumors" ], "interventions": [ { "name": "Surufatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hutchmed", "sponsor_class": "INDUSTRY", "healthy_volunteers": null, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2024-04-12", "last_synced_at": "2026-11-07T22:27:56.106Z", "location_count": 11, "location_summary": "Denver, Colorado • Baltimore, Maryland • Detroit, Michigan + 8 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Kansas City", "state": "Missouri" }, { "city": "Florham Park", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT04814732" }, { "nct_id": "NCT05228132", "title": "The Pristine Post-Market Study", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Kidney Failure, Chronic", "Hemodialysis Complication", "Hemodialysis Catheter Infection", "Hemodialysis Access Failure", "Central Venous Catheter Related Bloodstream Infection", "End Stage Renal Disease" ], "interventions": [ { "name": "Pristine™ Long-Term Hemodialysis Catheter", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "C. R. Bard", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 142, "start_date": "2022-05-16", "completion_date": "2022-09-21", "has_results": true, "last_update_posted_date": "2024-04-11", "last_synced_at": "2026-11-07T22:27:56.106Z", "location_count": 6, "location_summary": "Dothan, Alabama • New Haven, Connecticut • Shreveport, Louisiana + 3 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Shreveport", "state": "Louisiana" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Raleigh", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05228132" }, { "nct_id": "NCT06293898", "title": "Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Endometrial Cancer", "Cervical Cancer", "Ovarian Cancer", "Urothelial Carcinoma", "Biliary Tract Cancer", "Breast Cancer", "Lung Cancer", "Gastric Cancer", "Gastroesophageal-junction Cancer", "Esophageal Cancer" ], "interventions": [ { "name": "BL-M07D1", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SystImmune Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 280, "start_date": "2024-02-09", "completion_date": "2029-04-15", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-11-07T22:27:56.106Z", "location_count": 26, "location_summary": "Birmingham, Alabama • Duarte, California • Los Angeles, California + 19 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06293898" }, { "nct_id": "NCT01273493", "title": "A Pharmacokinetic Study of Trabectedin in Patients With Advanced Malignancies and Hepatic Dysfunction", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasm Metastases", "Hepatic Insufficiency" ], "interventions": [ { "name": "Trabectedin", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 15, "start_date": "2010-12", "completion_date": "2014-04", "has_results": false, "last_update_posted_date": "2016-02-15", "last_synced_at": "2026-11-07T22:27:56.106Z", "location_count": 6, "location_summary": "Scottsdale, Arizona • Detroit, Michigan • New York, New York + 3 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Detroit", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT01273493" }, { "nct_id": "NCT03454529", "title": "The Effect of Simvastatin on Breast Cancer Cell Growth in Women With Stage I-II Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Invasive Breast Carcinoma", "Stage I Breast Cancer AJCC v7", "Stage IA Breast Cancer AJCC v7", "Stage IB Breast Cancer AJCC v7", "Stage II Breast Cancer AJCC v6 and v7", "Stage IIA Breast Cancer AJCC v6 and v7", "Stage IIB Breast Cancer AJCC v6 and v7" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Simvastatin", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "Michael Simon", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "FEMALE", "summary": "19 Years and older · Female only" }, "enrollment_count": 24, "start_date": "2018-03-09", "completion_date": "2021-10-06", "has_results": true, "last_update_posted_date": "2023-08-01", "last_synced_at": "2026-11-07T22:27:56.106Z", "location_count": 1, "location_summary": "Detroit, Michigan", "locations": [ { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03454529" } ] }